Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Proteome Science
|
April 29, 2006
Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid
Nelson Guerreiro, Baltazar Gomez-Mancilla, Stéphane Charmont
Journal of Alzheimer'S Disease : JAD
|
March 13, 2008
Proteomic 2-D DIGE profiling of APP23 transgenic mice brain from pre-plaque and plaque phenotypes
Nelson Guerreiro, Matthias Staufenbiel, Baltazar Gomez-Mancilla
The AAPS Journal
|
February 8, 2021
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201
Nelson Guerreiro, Astrid Jullion, Stephane Ferretti, et al.
Toxicologic Pathology
|
December 25, 2003
Toxicogenomics in drug development
Nelson Guerreiro, Frank Staedtler, Olivier Grenet, et al.
Toxicology
|
March 16, 2005
T cell receptor (TCR) interaction with haptens: metal ions as non-classical haptens
Hermann-Josef Thierse, Katharina Gamerdinger, Christof Junkes, et al.
Journal of Molecular Microbiology and Biotechnology
|
July 21, 2004
Probing for pH-regulated proteins in Sinorhizobium medicae using proteomic analysis
Wayne G Reeve, Ravi P Tiwari, Nelson Guerreiro, et al.
Proteomics
|
August 13, 2005
Subproteomic analysis of metal-interacting proteins in human B cells
Kirsten Heiss, Christof Junkes, Nelson Guerreiro, et al.
Toxicology and Applied Pharmacology
|
November 18, 2010
Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers
Katja A Matheis, Emmanuelle Com, Jean-Charles Gautier, et al.
British Journal of Cancer
|
June 18, 2021
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
Sebastian Bauer, George D Demetri, Ensar Halilovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Albiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Proteome Science
|
April 29, 2006
Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid
Nelson Guerreiro, Baltazar Gomez-Mancilla, Stéphane Charmont
Journal of Alzheimer'S Disease : JAD
|
March 13, 2008
Proteomic 2-D DIGE profiling of APP23 transgenic mice brain from pre-plaque and plaque phenotypes
Nelson Guerreiro, Matthias Staufenbiel, Baltazar Gomez-Mancilla
The AAPS Journal
|
February 8, 2021
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201
Nelson Guerreiro, Astrid Jullion, Stephane Ferretti, et al.
Toxicologic Pathology
|
December 25, 2003
Toxicogenomics in drug development
Nelson Guerreiro, Frank Staedtler, Olivier Grenet, et al.
Toxicology
|
March 16, 2005
T cell receptor (TCR) interaction with haptens: metal ions as non-classical haptens
Hermann-Josef Thierse, Katharina Gamerdinger, Christof Junkes, et al.
Journal of Molecular Microbiology and Biotechnology
|
July 21, 2004
Probing for pH-regulated proteins in Sinorhizobium medicae using proteomic analysis
Wayne G Reeve, Ravi P Tiwari, Nelson Guerreiro, et al.
Proteomics
|
August 13, 2005
Subproteomic analysis of metal-interacting proteins in human B cells
Kirsten Heiss, Christof Junkes, Nelson Guerreiro, et al.
Toxicology and Applied Pharmacology
|
November 18, 2010
Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers
Katja A Matheis, Emmanuelle Com, Jean-Charles Gautier, et al.
British Journal of Cancer
|
June 18, 2021
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
Sebastian Bauer, George D Demetri, Ensar Halilovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Albiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
Page
of 2